OS Therapies enters USD 10 million line of credit backed by U.K. VAT, R&D tax credits

OS Therapies Incorporated

OS Therapies Incorporated

OSTX

0.00
  • OS Therapies entered a USD 10 million line of credit backed by VAT reimbursements and R&D tax credits at its UK subsidiary.
  • Borrowings must be repaid within nine months; the first USD 1.6 million draw is due by April 2, 2027.
  • Reported USD 5.6 million of outstanding VAT and R&D tax credits, with another USD 4.6 million expected to accrue by year-end 2026.
  • No security interest was granted in the company’s intellectual property.
  • Liquidity plan targets operations into 2027, with spending expected to moderate following recent regulatory dossier work.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607060900NEWSFILECNPR____20260706_304040_1) on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.